News

Growth charts of Sanfilippo patients, created in a German study, can help doctors predict the developmental progress of children affected by this rare disease, and counsel parents on what to expect, the researchers said. The charts, which show growth patterns of people with Sanfilippo syndrome from birth to early…

With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies (NCATS) at…

Abeona Therapeutics has started dosing the second group in its ongoing Phase 1/2 clinical trial testing ABO-101, treating the first patient with Sanfilippo syndrome type B with a high dose of the investigational gene therapy. This follows completion of the first part of the trial (NCT03315182), in…

Active tissue remodeling and treatment-resistant accumulation of toxic molecules are contributing factors in the development of persistent upper airway disease among patients with mucopolysaccharidosis (MPS), a study shows. The study, “Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme…

A new mutation in the SGSH gene associated with Sanfilippo syndrome type A, also known as mucopolysaccharidosis IIIA (MPS IIIA), was discovered in an 8-year-old girl in China, a case study reports. The study underscores the importance of a timely diagnosis…

Researchers at the National Institutes of Health have developed an induced pluripotent stem cell (iPSC) line from a 1-year-old child with a mutated NAGLU gene, the gene responsible for Sanfilippo syndrome type B. These cells may now be used to generate other mature cells, such as neurons, to investigate…

Abeona Therapeutics’ experimental gene therapy ABO-101 for people diagnosed with Sanfilippo syndrome type B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The company is currently enrolling eligible patients at sites across the U.S. and Spain for its Phase 1/2 trial. Fast Track designation is intended to…

Alpha-synuclein protein is not responsible for the onset of cognitive and motor symptoms associated with Sanfilippo syndrome type A, a mouse study suggests. The study, “Early disease course is unaltered in MPS IIIA mice lacking α‐synuclein,” was published in Neuropathology and Applied Neurobiology. Sanfilippo syndrome type…

Exome sequencing data — the DNA sequence of all genes encoding for proteins — that include the contribution of variants of unknown significance (VUS), may allow researchers to estimate accurately the incidence of rare genetic disorders, including Sanfilippo syndrome type B, a study suggests. The study, “…

Nonprofit research foundation Team Sanfilippo (TSF) is preparing to launch a Phase 2 clinical trial to explore the safety and efficacy of a common sugar called trehalose as a treatment for patients with Sanfilippo syndrome. This follows a collaborative agreement that was initially made with Bioblast Pharma, the therapy’s…